EGFR and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR)-activating mutations have been identified as a definitive predictive marker of the favorable efficacy for treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients2–5.